Conditions treated

Nuclear medicine therapies, some still in clinical trials, are used to treat these conditions:

Aug. 25, 2020
  1. Johnson GB (expert opinion). Mayo Clinic. March 9, 2020.
  2. Kendi AT (expert opinion). Mayo Clinic. May 29, 2019.
  3. Office of Patient Education. Peptide receptor radionuclide therapy (PRRT) for somatostatin-positive tumors. Mayo Clinic; 2018.
  4. Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. New England Journal of Medicine 2017; doi:10.1056/NEJMoa1607427.
  5. U.S. Food and Drug Administration (news release). FDA approves new treatment for certain digestive tract cancers. Jan. 26, 2018. Accessed May 24, 2018.
  6. National Cancer Institute (news release). FDA approves new treatment for certain neuroendocrine tumors. Feb. 8, 2018. Accessed May 24, 2018.
  7. Warner KJ. Allscripts EPSi. Mayo Clinic. April 29, 2019.
  8. Kendi AT, et al. Therapy with 177Lu-DOTATE: Clinical implementation and impact on care of patients with neuroendocrine tumors. American Journal of Roentgenology. 2019; doi:10.2214/AJR.19.21123.
  9. Halfdanarson, TR (expert opinion). Mayo Clinic. March 11, 2020.